Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Understanding Second-Line Osteoporosis Pharmacotherapy in Older Men and Women

EF 2019-20

Résumé
"Osteoporosis is a brittle bone condition that results in debilitating fractures. Over 2 million Canadians are affected by osteoporosis, and 1 in 3 women and 1 in 5 men will experience an osteoporotic fracture. Vertebral fractures reduce quality of life and are often accompanied by difficulty breathing and stomach issues related to a forward curvature of the upper spine. Hip fractures are deadly, 5% of patients do not survive their hospitalization and up to 33% die within the year after hip fracture. In addition, up to 24% enter a nursing home for the first time following hip fracture. Thankfully, there are a variety of medications available to strengthen bones and reduce fracture risk. In Ontario, residents over the age of 65 receive drug coverage through the Ontario Drug Benefit program. First-line medication options for osteoporosis include oral bisphosphonates and raloxifene, which are taken by mouth. However, some patients stop taking their medications because they are not working well enough, or patients are unable to tolerate them. As a result, these patients need to switch to more potent therapies, including annual zoledronic acid or the twice a year injectable denosumab which became covered for women only in 2012. Uncertainty about which therapy should be used, an annual infusion of zoledronic acid or the semi-annual denosumab, was a knowledge gap identified in Osteoporosis Canada's Clinical Practice Guidelines that are currently being updated. We are working directly with Osteoporosis Canada to answer questions about second-line therapy for osteoporosis. Results will inform long-term treatment decisions for older men and women and thus significantly advance osteoporosis management world-wide."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428922
Name
Konstantelos Natalia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Understanding Second-Line Osteoporosis Pharmacotherapy in Older Men and Women
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Utilization; Gender And Health; Health Services Research; Musculoskeletal Health; Osteoporosis; Pharmacoepidemiology; Regional Differences
Abstract
"Osteoporosis is a brittle bone condition that results in debilitating fractures. Over 2 million Canadians are affected by osteoporosis, and 1 in 3 women and 1 in 5 men will experience an osteoporotic fracture. Vertebral fractures reduce quality of life and are often accompanied by difficulty breathing and stomach issues related to a forward curvature of the upper spine. Hip fractures are deadly, 5% of patients do not survive their hospitalization and up to 33% die within the year after hip fracture. In addition, up to 24% enter a nursing home for the first time following hip fracture. Thankfully, there are a variety of medications available to strengthen bones and reduce fracture risk. In Ontario, residents over the age of 65 receive drug coverage through the Ontario Drug Benefit program. First-line medication options for osteoporosis include oral bisphosphonates and raloxifene, which are taken by mouth. However, some patients stop taking their medications because they are not working well enough, or patients are unable to tolerate them. As a result, these patients need to switch to more potent therapies, including annual zoledronic acid or the twice a year injectable denosumab which became covered for women only in 2012. Uncertainty about which therapy should be used, an annual infusion of zoledronic acid or the semi-annual denosumab, was a knowledge gap identified in Osteoporosis Canada's Clinical Practice Guidelines that are currently being updated. We are working directly with Osteoporosis Canada to answer questions about second-line therapy for osteoporosis. Results will inform long-term treatment decisions for older men and women and thus significantly advance osteoporosis management world-wide."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Konstantelos, Natalia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~